ReferenceGrowth-hormone secretagogue research
CJC-1295
CJC-1295 DAC · CJC-1295 no-DAC · Mod GRF 1-29 · GHRH analog
Long-acting GHRH analog studied in growth-hormone-releasing research.
About CJC-1295
CJC-1295 is a modified growth-hormone-releasing hormone (GHRH) analog studied for its extended half-life, available in research literature both with the Drug Affinity Complex (DAC) and without it (Mod GRF 1-29). It is a standard reference GHRH analog. TagPep is adding CJC-1295 as a research-use-only reference material.
Mechanism studied in research
Agonism at the GHRH receptor; the DAC variant binds albumin to extend circulation time, a property studied in half-life and pulsatility research.
Areas of research investigation
- GHRH-receptor signaling assays
- Peptide half-life extension research
- GH-axis model systems
- Secretagogue combination studies
Laboratory handling
Lyophilized; research reconstitution with bacteriostatic or sterile water, refrigerated solution, frozen light-protected powder.
CJC-1295 research FAQ
What is the difference between CJC-1295 with and without DAC?
The DAC (Drug Affinity Complex) version binds albumin for a much longer half-life; the no-DAC version (Mod GRF 1-29) is shorter-acting. Both are studied as GHRH analogs.
Is CJC-1295 a growth hormone?
No — it is a GHRH analog studied for stimulating the GH axis, not growth hormone itself.
Research use only. CJC-1295 is supplied as a laboratory reference material for in-vitro and research applications. It is not a drug, supplement or medical product, and is not intended for human or veterinary use, consumption, or clinical application.